Carvykti (ciltacabtagene autoleucel)

Numéro de dossier de l’AMC: 22363
État des négociations:
En négociation
Indication(s):
Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.
Promoteur/fabricant:
Janssen Inc.
Numéro de projet de l’AMC:
PG0302-000
Lettre d’entente de l’APP:
Conclusion du processus de négociation:
Sans objet